References
- Keating M J, Flinn I, Jain V, Binet J L, Hillmen P, Byrd J, et al. Theraputic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–3561
- Faderl S, Coutré S, Byrd J C, Dearden C, Denes A, Dyer M J, et al. The evolving role of Alemtuzumab in management of patients with CLL. Leukemia 2005; 19: 2147–2152
- Otton S H, Turner D L, Frewin R, Davies S V, Johnson S A. Autoimmune thrombocytopenia after treatment with Campath 1H in a patient with chronic lymphocytic leukaemia. Br J Haematol 1999; 106: 252–262
- Killick S B, Marsh J CW, Hale G, Waldmann H, Kelly S J, Gordon-Smith E C. Sustained remission of severe resistant autoimmune neutropenia with Campath-1H. Br J Haematol 1997; 97: 306–308
- Willis F, Marsh J CW, Bevan D H, Killick S B, Lucas G, Griffiths R, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol 2001; 114: 891–898
- Marsh J CW, Gordon-Smith E C. Campath-1H in the treatment of aoutimmune cytopenias. Cytotherapy 2001; 3: 189–195
- Cheung W W, Hwang G Y, Tse E, Kwong Y L. Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab. Haematologica 2006; 91: ECR13
- Rodon P, Breton P, Courouble G. Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukaemia with Campath-1H. Eur J Haematol 2003; 70: 319–321
- Lundin J, Karlsson C, Celsing F. ‘Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia. Med Oncol 2006; 23: 137–139
- Garratty G. Immune hemolytic anemia associated with negative routine serology. Semin Hematol 2005; 42: 156–164
- Fischer L, Penaci O, Gentilizi C, Nagai A, Muessig A, Thiel E, et al. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Exp Hematol 2006; 34: 753–759